Clinical trials: Adult Depression
Major Depressive Disorder
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.
- Trial name
- NCT04830215
- Testing
- Brexpiprazole
- Where
- Canada
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Vasomotor Symptoms
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
- Trial name
- NCT01353963
- Testing
- desvenlafaxine succinate
- Where
- 3 sites in Philippines
- Volunteers
- 13 people
- Sponsor
- Pfizer
Orthopedic Surgery, Older Adults
Perioperative Mental Health in Orthopedic Surgery
This Hybrid 1 Study will test the effectiveness of a bundled intervention comprised of behavioral activation and medication optimization in reducing symptoms of depression and anxiety in older adults undergoing Orthopedic surgery…
- Conditions
- Orthopedic Surgery, Older Adults, Depression, Anxiety
- Trial name
- CPMH (NCT05697835)
- Testing
- Behavioral activation, Medication optimzation, Care as usual
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Washington University School of Medicine
Osteoarthritis (OA)
Effect of Chair Yoga on Elders With Osteoarthritis
The current study is a two-arm randomized controlled clinical trial to test the feasibility of recruiting, randomizing, and having older adults with osteoarthritis (OA) adhere to and safely complete the 8-week Sit 'N' Fit Chair…
- Trial name
- NCT02113410
- Testing
- Sit 'N' Fit Chair Yoga (SNFCY), Health Education Program (HEP)
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- Florida Atlantic University
Executive Dysfunction, Depression
iTBS Study for Depression (Randomized)
Executive function deficits are common in late life depression (LLD) and are associated with resistance to antidepressants, poor quality of life, considerable disability and increased suicidal risk.
- Trial name
- NCT03745768
- Testing
- Intermittent Theta Burst Stimulation
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Cancer, Bone Marrow Neoplasms
The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation
Multisite Randomized Controlled Trial (RCT) testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults receiving hematopoietic cell transplantation for hematology…
- Conditions
- Cancer, Bone Marrow Neoplasms, Anxiety, Depression
- Trial name
- NCT03640325
- Testing
- PRISM (Promoting Resilience in Stress Management)
- Where
- 5 sites in United States
- Volunteers
- 143 people
- Sponsor
- Seattle Children's Hospital
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate the efficacy, tolerability and the safety of two fixed doses of vortioxetine in the treatment of major depressive disorder.
- Trial name
- NCT01140906
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 607 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with…
- Trial name
- NCT04599855
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 54 sites in United States
- Volunteers
- 477 people
- Sponsor
- Janssen Research & Development, LLC
Depression Mild, Depressive Disorder, Major
Cognitive Fitness for Depression in Older Adults
This research is being done to determine if computerized administered cognitive fitness activities will improve thinking and depression in older depressed adults who are being treated with antidepressants.
- Conditions
- Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
- Trial name
- NCT04790630
- Testing
- Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- UConn Health
Treatment-Resistant Depression
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant…
- Trial name
- NCT05454410
- Testing
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg
- Where
- 16 sites in United States, Japan and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19, Cardiorespiratory Failure
Lift Mobile Mindfulness for COVID-19 Distress Symptoms
This is a randomized clinical trial (RCT) nested within the NIH PETAL Network's COVID cohort study (BLUE CORAL [Biology and Longitudinal Epidemiology: COVID Observational Study]) of patients hospitalized for COVID-19-related…
- Trial name
- LIFTCOVID (NCT04581200)
- Testing
- Lift
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Duke University
Depression
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of this study is to evaluate the safety and tolerability of long term (6 months) armodafinil treatment as adjunctive therapy to mood-stabilizing medications in adults with bipolar I disorder.
- Trial name
- NCT01121536
- Testing
- Armodafinil
- Where
- 158 sites in United States, Argentina and 15 more
- Volunteers
- 867 people
- Sponsor
- Cephalon
Major Depressive Disorder
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD
In this randomized clinical trial, subjects will be assigned to either an assay-guided treatment condition (AGT) or a treatment-as-usual condition (TAU).
- Trial name
- NCT02634177
- Testing
- Assay-guided treatment (AGT), Treatment-as-usual (TAU)
- Where
- 23 sites in United States
- Volunteers
- 305 people
- Sponsor
- Genomind, LLC
Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
Major Depressive Disorder
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder (MDD) is a severe and common psychiatric disorder. Although MDD primarily involves mood disturbances, patients also usually present alterations in cognitive function (attention, memory, executive…
- Trial name
- FOCUS (NCT01422213)
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 598 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Depression
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Orion (NCT01360866)
- Testing
- OPC-34712, Escitalopram, Fluoxetine
- Where
- 142 sites in United States, Canada and 9 more
- Volunteers
- 2,944 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an…
- Trial name
- NCT03321526
- Testing
- JNJ-42847922, Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- 50 sites in United States
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00839423
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine XL
- Volunteers
- 426 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
- Trial name
- NCT00905424
- Testing
- Antidepressant + SPD489 (lisdexamfetamine dimesylate)
- Where
- 15 sites in United States
- Volunteers
- 246 people
- Sponsor
- Shire
Schizophrenia, Major Depressive Disorder
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT02722967
- Testing
- Aripiprazole + IEM (Ingestible Event Marker)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.